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Background: Objectives:The scaffold shrinkage detected in the first generation device has been fully remediated with the second generation, fully 
bioresorbable, everolimus-eluting ABSORB scaffold with changes in design platform and manufacturing process. Further sequential follow-up with 
invasive imaging was warranted the investigation of the long-term safety and efficacy as well as vascular changes following this treatment.
Methods: The ABSORB Cohort B trial is a multicentre single-arm trial assessing the safety and performance of the ABSORB BVS (Rev.1.1, Abbott 
Vascular, Santa Clara, USA) in the treatment of patients with a maximum of two de novo native coronary artery lesions. The first 45 patients (Cohort 
B1) underwent serial invasive imaging follow-up at 6 and 24 months, including angiography, IVUS and OCT.
Results: There was one periprocedural myocardial infarction and two proximal edge target lesion revascularizations, which resulted in 2-year major 
adverse cardiac event rate of 6.8%. Quantitative coronary angiography demonstrated a 2-year in-scaffold late loss of 0.27±0.20mm. In IVUS, the 
mean scaffold area significantly increased from 6 months to 2 years with a global increase of 0.54 mm2, which was also confirmed with OCT. IVUS 
demonstrated a significant increase in mean lumen area and vessel area from 6M to 2 years, suggesting a positive vessel remodeling with late 
lumen enlargement, except for the site of minimal lumen area. On OCT, struts are still recognizable at 2 years. Neointimal area increased from 6 
months (1.43mm2) to 2 years (2.11mm2) but remained minimal with complete strut coverage.
Conclusions: The current report confirms long-term safety and efficacy of the ABSORB scaffold. Late scaffold and lumen enlargement observed 
with the current study needs to be further investigated in the later follow-up (3 years).
